Rapid onset bronchodilation with formoterol or salbutamol in patients with chronic obstructive pulmonary disease (COPD)
D. Benhamou, J. F. Muir, V. Leclerc, V. Le Gros, I. Bourdeix (Rouen, Paris, Rueil-Malmaison, France)
Source: Annual Congress 2001 - Long-acting β2-agonists: clinical effects
Session: Long-acting β2-agonists: clinical effects
Session type: Oral Presentation
Number: 3470
Disease area: Airway diseases
Abstract A rapid onset of action is important for bronchodilator therapy to provide relief from dyspnoea in patients with COPD. METHODS: A randomized, placebo-controlled, 3-way cross-over trial was conducted, double-blind for formoterol and placebo, single-blind for salbutamol. Changes in FEV1 were monitored over the 3 hours following single doses of formoterol 24 μg (Foradil® 12 μg, 2 capsules delivered via Aerolizer™ dry powder inhaler), salbutamol 400 μg (Ventodisk™ 200 μg, 2 puffs) and placebo. RESULTS: 24 COPD patients were randomized (20 males; mean±]SD age 61.6±]7.8 years; FEV1 1.38±]0.32 L, 45.8±]9.6% of predicted, 13.5±]4.8% reversibility). Formoterol and salbutamol each elicited similar bronchodilation until 3 hours post-dose, with an increase in FEV1 of approximately 15% above baseline by 5 minutes, and near-maximal bronchodilation by 30 minutes. Changes in FEV1 area under the curve from 0 to 30 minutes with formoterol (5.89±]4.67 L) or salbutamol (6.06±]4.34 L) were similar and significantly higher than with placebo (-0.32±]2.59 L) (p<0.0001). CONCLUSION: Formoterol 24 μg and salbutamol 400 μg produce a rapid and similar onset of action in COPD patients, providing prompt relief from dyspnoea in patients with limited FEV1 reversibility.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Benhamou, J. F. Muir, V. Leclerc, V. Le Gros, I. Bourdeix (Rouen, Paris, Rueil-Malmaison, France). Rapid onset bronchodilation with formoterol or salbutamol in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 2001; 16: Suppl. 31, 3470
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 639-644 Year: 2002
Bronchodilator responsiveness in patients with COPD Source: Eur Respir J 2008; 31: 742-750 Year: 2008
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007
Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) and COPD concomitant with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 521s Year: 2004
Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Source: Eur Respir J 2002; 19: 936-943 Year: 2002
Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history Source: Eur Respir J 2011; 38: 553-560 Year: 2011
A comparison of bronchodilating response of salbutamol, ipratropium bromide and the combination of ipratropium-salbutamol in patients with stable chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001
Audit of inhaled corticosteroid prescription in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: management Year: 2010
A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations Source: Eur Respir J 2013; 41: 12-17 Year: 2013
Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 427s Year: 2003
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002
Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001